Adrenergic alpha receptor (Alpha-AR)

Molecular Classification

G protein-coupled receptor (GPCR), Receptor

Other Names

Alpha-adrenergic receptor, Alpha-AR, α-adrenergic receptor, α-AR, Adrenergic receptor alpha, α1-adrenergic receptor (for the α1 subtype), α2-adrenergic receptor (for the α2 subtype), α1A, α1B, α1D (subtypes of α1-AR), α2A, α2B, α2C (subtypes of α2-AR)

Disease Roles

Cardiovascular disease (hypertension, shock, heart failure)Prostate disease (benign prostatic hyperplasia)PTSD (alpha-1 antagonists off-label)

Adrenergic alpha receptor Overview

Adrenergic alpha receptors are members of the G protein-coupled receptor (GPCR) superfamily that bind catecholamines, primarily norepinephrine and epinephrine, mediating key physiological roles in the cardiovascular, nervous, and other organ systems. There are two primary classes—alpha-1 and alpha-2—each with multiple human subtypes (α1A, α1B, α1D; α2A, α2B, α2C) that differ in distribution, signaling, and pharmacology. Alpha-1 receptors primarily induce vasoconstriction by activating smooth muscle, modulate cardiac hypertrophy, and influence glandular secretion and cognition. Alpha-2 receptors modulate neurotransmitter release and sympathetic tone (mostly through feedback inhibition). Alpha-adrenergic receptors are major drug targets for managing blood pressure, cardiac failure, urinary tract symptoms, and other sympathetic nervous system disorders. Their activity is manipulated by a large range of clinically used agonists and antagonists, with selectivity for subtypes allowing tailored therapy.

Mechanism of Action

Agonists: Stimulate alpha receptors, leading to vasoconstriction, increased peripheral vascular resistance, mydriasis, decreased secretions, and other sympathetic nervous system effects. Antagonists: Block alpha receptors, resulting in vasodilation, reduced blood pressure, relaxation of smooth muscle in the urinary tract, and reduced resistance in vascular smooth muscle.

Biological Functions

Signal transduction

Vasoconstriction (smooth muscle contraction)

Regulation of blood pressure

Neurotransmission

Regulation of cardiac function

Metabolism

Regulation of glandular secretion

Cognition

Angiogenesis

Disease Associations

Cardiovascular disease (hypertension, shock, heart failure)

Prostate disease (benign prostatic hyperplasia)

PTSD (alpha-1 antagonists off-label)

Pheochromocytoma (pre-operative management)

Metabolic disorders

Other conditions involving sympathetic dysregulation

Safety Considerations

Agonists: Hypertension, reflex bradycardia, ischemia, arrhythmias, tissue necrosis if extravasated (for IV drugs)
Antagonists: Orthostatic hypotension, syncope, dizziness, nasal congestion, tachycardia, first-dose phenomenon (notably with prazosin), sexual dysfunction
Non-selectivity risks: Off-target beta-AR or other GPCR-related effects

Interacting Drugs

Agonists: Phenylephrine, methoxamine, oxymetazoline, norepinephrine (noradrenaline), epinephrine (adrenaline), A61603 (research)

Antagonists (alpha-blockers): Prazosin, doxazosin, tamsulosin, phentolamine, phenoxybenzamine, terazosin, alfuzosin, silodosin, yohimbine

Other adrenergics: Dopamine, epinephrine, norepinephrine (non-selective at high doses)

Associated Biomarkers

Biomarker
None specific identified for routine clinical use; receptor density or genetic polymorphisms may be used in research settings or specialized studies
Blood pressure response to agonists/antagonists is sometimes used to gauge function in clinical practice
Heart rate variability and vascular reactivity (research context)